Savella
indicated to manage central nervous system signaling to alleviate physical pain in fibromyalgia.
Strengths: 25mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
- Pharmacological class
SNRI
- Minor side effects
nausea; headache; constipation; dizziness
- Moderate side effects
palpitations; hypertension; insomnia
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Allergan
- Onset Time
2–4 weeks
- Duration
12–24 hours
- Storage instructions
Store in a dry location at controlled temperature.
- Drug interactions
MAO inhibitors; aspirin; NSAIDs
- Age restrictions
Not established for use in children.
- Pregnancy and breastfeeding
Pregnancy: Avoid unless necessary. Breastfeeding: Not recommended.
Contraindications
hypersensitivity to milnacipran; narrow-angle glaucoma; concurrent use of MAO inhibitors
Precautions and warnings
monitor blood pressure and heart rate; use with care in patients with seizure disorders; observe for signs of suicidal thinking
Serious side effects
serotonin syndrome — requires immediate medical attention; suicidal ideation — requires immediate medical attention
Patient summary
indicated to manage central nervous system signaling to alleviate physical pain in fibromyalgia.
Mechanism of action
This medication functions as a neurotransmitter modulator. By inhibiting the reuptake of both norepinephrine and serotonin, it increases the availability of these chemicals in the synapse, which helps in modulating pain pathways.
Savella
indicated to manage central nervous system signaling to alleviate physical pain in fibromyalgia.
Editorial Notes
- Active ingredient(s): Milnacipran
- Listed indication(s): Fibromyalgia
Available option
- 100 tablets - 25 mg1465-25-mg-17669